The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019…
Read More
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…
Although substantial concerns about the inflammatory effects of engineered nanomaterial (ENM) have been raised, experimentally assessing toxicity of various ENMs is challenging and time-consuming. Alternatively, quantitative structure–activity relationship (QSAR) models…
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune…
Oncology Scientific Advisory Board to support advancement of Immuneering’s drug programs modulating the RAS/MAPK signaling pathway in cancer CAMBRIDGE, Mass. – March 25, 2020 – Immuneering Corporation today announced…
Published: Jan 28, 2020 By Alex Keown In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a…
IMMUNEERING RAISES $20 MILLION FOR NEW DRUG-DISCOVERY EFFORT Company formed in 2008 also provides services to pharmaceutical companies By Brian Gormley Venture capitalists are betting $20 million that…
FINANCING TO FUND IMMUNEERING’S PIPELINE INCLUDING PROGRAMS IN CANCER CACHEXIA, NEXT-GENERATION KRAS INHIBITION AND THE RAF-MEK PATHWAY, ALL DRIVEN BY ITS DISEASE CANCELLING TECHNOLOGY CAMBRIDGE, Mass. – Jan. 22,…
On this episode of The Bio Report podcast Immuneering co-founder and CEO Ben Zeskind discusses the company’s evolution from its roots in bioinformatics, movement into drug development, and the proprietary…
CANCER IMMUNOTHERAPY LEADER JOINS IMMUNEERING’S EXECUTIVE TEAM TO APPLY THE COMPANY’S DISEASE CANCELLING TECHNOLOGY TO IMMUNO-ONCOLOGY CAMBRIDGE, Mass. – Jan. 9, 2020 – Immuneering Corporation today announced an addition…
